Indications for Systemic Chemotherapy

  • Anna Nappi
  • Gugliemo Nasti
  • Alessandro Ottaiano
  • Antonino Cassata
  • Carmela Romano
  • Rossana Casaretti
  • Lucrezia Silvestro
  • Salvatore Tafuto
  • Chiara De Divitiis
  • Antonio Avallone
  • Rosario V. IaffaioliEmail author
Part of the Updates in Surgery book series (UPDATESSURG)


Local recurrence (LR) after curative surgery is a critical problem for patients with colorectal cancer (CRC). Over the last two decades, oncologic treatment results for primary rectal cancer have improved due to refinements in neoadjuvant chemotherapy, radiation, and surgery. Nevertheless, there is still a 5–10% rate of LR, threatening the survival and quality of life of affected patients [1]. LR is best defined as any tumor recurring within the true pelvis, including neorectum, mesentery, pelvic viscera, pelvic sidewall structures, and bone. Due to variability of anatomy and clinical presentation, detection, staging, and clinical management are complex. About half of all LRs are limited to the pelvis and can be considered for curative re-excision [2] (Table 6.1).


Overall Survival Rectal Cancer Total Mesorectal Excision Overall Response Rate Optimal Treatment Strategy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Heriot AG, Byrne CM, Lee P et al (2008) Extended radical resection: the choice for locally recurrent rectal cancer. Dis Colon Rectum 51:284–291CrossRefPubMedGoogle Scholar
  2. 2.
    Heald RJ (1995) Total mesorectal excision is optimal surgery for rectal cancer: a Scandinavian consensus. Br J Surg 82:1297–1299CrossRefPubMedGoogle Scholar
  3. 3.
    Guillem JG, Chessin DB, Cohen AM et al (2005) Longterm oncologic outcome following pre-operative combined modality therapy and total mesorectal excision of locally advanced rectal cancer. Ann Surg 241:829 (discussion 836–828)PubMedCentralCrossRefPubMedGoogle Scholar
  4. 4.
    Wanebo HJ, Antoniuk P, Koness RJ et al (1999) Pelvic resection of recurrent rectal cancer: technical considerations and outcomes. Dis Colon Rectum 42:1438-1448CrossRefPubMedGoogle Scholar
  5. 5.
    Heriot AG, Byrne CM, Lee P et al (2008) Extended radical resection: the choice for locally recurrent rectal cancer. Dis Colon Rectum 51:284-291CrossRefPubMedGoogle Scholar
  6. 6.
    Yamada K, Ishizawat T, Niwa K et al (2001) Patterns of pelvic invasion are prognostic in the treatment of locally recurrent rectal cancer. Br J Surg 88:988-993CrossRefPubMedGoogle Scholar
  7. 7.
    Jimenez RE, Shoup M, Cohen AM et al (2003) Contemporary outcomes of total pelvic exenteration in the treatment of colorectal cancer. Dis Colon Rectum 46:1619-1625CrossRefPubMedGoogle Scholar
  8. 8.
    Yeo HL, Paty PB (2014) Management of Recurrent Rectal Cancer: Practical Insights in Planning and Surgical Intervention. J Surg Onc 109:47-52CrossRefGoogle Scholar
  9. 9.
    Bouchard P, Efron J (2010) Management of recurrent rectal cancer. Ann Surg Oncol 17:1343–1356CrossRefPubMedGoogle Scholar
  10. 10.
    Primrose JN, Perera R et al (2014) Effect of 3 to 5 years of scheduled CEA and follow-up to detect recurrence of colorectal cancer. The FACS randomized clinical trial. JAMA 311:263-270CrossRefPubMedGoogle Scholar
  11. 11.
    Platell C, Spilsbury K (2014) Influence of local recurrence on survival in patients with rectal cancer. ANZ J Surg 84:85–90CrossRefPubMedGoogle Scholar
  12. 12.
    Sagar PM, Pemberton JH (1996) Surgical management of locally recurrent rectal cancer. Br J Surg 83:293–304CrossRefPubMedGoogle Scholar
  13. 13.
    Lopez-Kostner F, Fazio VW et al (2001) Locally recurrent rectal cancer: predictors and success of salvage surgery. Dis Colon Rectum 44:173–178CrossRefPubMedGoogle Scholar
  14. 14.
    Mirnezami AH, Sagar PM et al (2010) Clinical algorithms for the surgical management of locally recurrent rectal cancer. Dis Colon Rectum 53:1248–1257CrossRefPubMedGoogle Scholar
  15. 15.
    Harris DA, Davies M et al (2011) Multivisceral resection for primary locally advanced rectal carcinoma. Br J Surg 98:582–588CrossRefPubMedGoogle Scholar
  16. 16.
    Nordlinger B et al (2008) Perooperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomized controlled trial. Lancet 371:1007–1016PubMedCentralCrossRefPubMedGoogle Scholar
  17. 17.
    Haddock MG, Miller RC et al (2011) Combined modality therapy including intraoperative electron irradiation for locally recurrent colorectal cancer. Int J Radiat Oncol Biol Phys 79:143–150CrossRefPubMedGoogle Scholar
  18. 18.
    Heinemann V, von Weikersthal L, Decker T et al (2013) FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. J Clin Oncol 31(suppl)Google Scholar
  19. 19.
    Loupakis F, Cremolini C et al (2014) Initial therapy with FOLFOXIRI and Bevacizumab for metastatic colo rectal cancer. N Engl J Med 371:1609–1618CrossRefPubMedGoogle Scholar
  20. 20.
    Falcone A, Cremolini C, Masi G et al (2013) FOLFOXIRI/bevacizumab (bev) versus FOLFIRI/bev as first-line treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): results of the phase III TRIBE trial by GONO group (abstract 3505). J Clin Oncol 31(suppl)Google Scholar
  21. 21.
    Lee S. Schwartzberg et al (2013) PEAK: a randomized, multicenter phase ii study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS Ex-on 2 metastatic colorectal cancer. J Clin Oncol 32:2240–2247Google Scholar
  22. 22.
    Van Cutsem E, Cervantes A, Nordlinger B, Arnold D; ESMO Guidelines Working Group (2014) Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 25(Suppl 3):iii1–iii9CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Italia 2016

Authors and Affiliations

  • Anna Nappi
  • Gugliemo Nasti
  • Alessandro Ottaiano
  • Antonino Cassata
  • Carmela Romano
  • Rossana Casaretti
  • Lucrezia Silvestro
  • Salvatore Tafuto
  • Chiara De Divitiis
  • Antonio Avallone
  • Rosario V. Iaffaioli
    • 1
    Email author
  1. 1.Medical Abdominal Oncology, Department of Abdominal OncologyIstituto Nazionale Tumori - IRCCS Fondazione G. PascaleNaplesItaly

Personalised recommendations